Drug Profile
Trastuzumab biosimilar - Harvest Moon Pharmaceuticals
Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Breast-cancer in USA
- 18 Jun 2015 Trastuzumab biosimilar - Harvest Moon Pharmaceuticals is available for licensing as of 18 Jun 2015. www.harvestmoonpharma.com
- 09 Jun 2015 Biosimilars no longer licensed to PanPharmaceuticals USA